Endothelial Progenitor Cells

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by Far Eastern Memorial Hospital.
Recruitment status was  Recruiting
Information provided by:
Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier:
First received: February 6, 2009
Last updated: September 12, 2012
Last verified: January 2007
Vascular stenosis as a result of neointimal hyperplasia is a major clinical problem that has an impact on multiple and diverse disciplines, including cardiology (coronary restenosis), cardiothoracic and vascular surgery (saphenous vein and polytetrafluoroethylene [PTFE] graft failure), neurology (carotid stenosis), nephrology (dialysis access dysfunction), and transplant medicine (chronic allograft rejection in hearts and kidneys). [1] In marked contrast to the deleterious effects of smooth muscle progenitor cells on neointimal hyperplasia, circulating endothelial progenitor cells (EPCs) are believed to play an important role in vascular repair and in the inhibition of neointimal hyperplasia. [2] Endothelial progenitor cells (EPCs) circulate in adult peripheral blood and contribute to neovascularization. Satoshi et al. have demonstrated that lineage-committed EPCs and CD34-positive mononuclear cells, their putative precursors, are mobilized during an acute ischemic event in humans. [3] Reduced levels of circulating EPCs independently predict atherosclerotic disease progression, thus supporting an important role for endogenous vascular repair to modulate the clinical course of coronary artery disease. [4] These observations prompt the hypothesis that circulating EPCs may provide an endogenous repair mechanism to counteract surgery-induced endothelial cell injury and to replace dysfunctional endothelium perioperatively. Therefore, the investigators examined whether levels of circulating EPCs correlate with time course and outcomes of coronary artery bypass surgery to establish a clinical role of endogenous endothelial repair mediated by circulating EPCs.

Condition Intervention
Coronary Artery Disease
Procedure: blood collecting

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Mobilization of Endothelial Progenitor Cells in Patients With Coronary Artery Bypass Surgery

Resource links provided by NLM:

Further study details as provided by Far Eastern Memorial Hospital:

Estimated Enrollment: 50
Study Start Date: March 2007

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age from 18 to 85 years
  • signed written informed consent
  • angiographically documented coronary artery disease and indicated for coronary artery bypass surgery

Exclusion Criteria:

  • clinical or biochemical evidence for the presence of concomitant inflammatory disease
  • chronic renal insufficiency (serum creatinine > 1.4 mmol/L)
  • impaired left ventricular ejection fraction (< 45%)
  • autoimmune or malignant disease
  • thrombocytopenia (< 100 000/L)
  • anemia (hemoglobin < 8.5 g/dL)
  • inability to understand the consent form
  • previous coronary bypass surgery
  • severe peripheral arterial occlusive disease or atrial fibrillation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01686269

Contact: Kuan-MIng Chiu, MD 886-2-89667000 kmchius@yahoo.com.tw

Far Eastern Memorial Hospital Recruiting
Taipei, Taiwan, 220
Contact: Kuan-Ming Chiu, MD    886-2-89667000    kmchius@yahoo.com.tw   
Principal Investigator: Kuan-Ming Chiu, MD         
Sponsors and Collaborators
Far Eastern Memorial Hospital
Study Director: Kuan-Ming Chiu, MD Far Eastern Memorial Hospital
  More Information

ClinicalTrials.gov Identifier: NCT01686269     History of Changes
Other Study ID Numbers: FEMH-95-C-018 
Study First Received: February 6, 2009
Last Updated: September 12, 2012
Health Authority: Taiwan: Department of Health

Keywords provided by Far Eastern Memorial Hospital:
Endothelial progenitor cell
coronary artery bypass

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Heart Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on May 23, 2016